EOLS Evolus, Inc.
Stock · NasdaqGM · United States · Healthcare · US30052C1071
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Evolus, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
6.81 USD
+0.15%
52-week range
3.86 – 9.31
Dividend yield—
Market cap450.4M
NowoTrade score
37 Grade A
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:53. Information, not advice.
Results
Next results
02 Mar 2027
in 114 days · 16:00 · estimate 0.05
Last results
-0.04 vs -0.07 estimated
04 Nov 2026 · Beat +34.2%
Beat the estimate
4 of 12
8 missed · 0 in line · 3 beats in a row
Average surprise
-29.1%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 02 Mar 2027 16:00 | 0.05 | — | — | Upcoming |
| 04 Nov 2026 16:00 | -0.07 | -0.04 | +34.2% | Beat |
| 05 Aug 2026 16:00 | -0.04 | -0.02 | +52.6% | Beat |
| 04 May 2026 16:00 | -0.12 | -0.05 | +57.9% | Beat |
| 03 Mar 2026 16:00 | 0.04 | 0.01 | -64.8% | Miss |
| 05 Nov 2025 16:00 | -0.18 | -0.15 | +19.4% | Beat |
| 05 Aug 2025 16:00 | -0.09 | -0.26 | -175.1% | Miss |
| 07 May 2025 16:00 | -0.14 | -0.17 | -18.6% | Miss |
| 04 Mar 2025 16:00 | 0.02 | 0.01 | -37.8% | Miss |
| 06 Nov 2024 16:00 | -0.11 | -0.18 | -66.7% | Miss |
| 31 Jul 2024 16:00 | -0.06 | -0.06 | -6.4% | Miss |
| 07 May 2024 16:00 | -0.08 | -0.11 | -34.6% | Miss |
| 07 Mar 2024 16:00 | -0.07 | -0.14 | -109.0% | Miss |
| 07 Nov 2023 16:00 | -0.18 | -0.18 | -0.9% | In line |
| 02 Aug 2023 16:00 | -0.20 | -0.22 | -6.4% | Miss |
| 09 May 2023 16:00 | -0.16 | -0.17 | -10.4% | Miss |
| 08 Mar 2023 16:00 | -0.14 | -0.16 | -13.7% | Miss |
| 08 Nov 2022 16:00 | -0.29 | -0.29 | -3.0% | Miss |
| 02 Aug 2022 08:00 | -0.24 | -0.30 | -25.5% | Miss |
| 10 May 2022 17:00 | -0.33 | -0.24 | +27.5% | Beat |
| 03 Mar 2022 16:00 | -0.21 | -0.24 | -12.3% | Miss |
| 02 Nov 2021 08:00 | -0.27 | -0.28 | -6.3% | Miss |
| 04 Aug 2021 16:00 | -0.25 | -0.19 | +24.8% | Beat |
| 12 May 2021 17:00 | -0.42 | 0.20 | +148.0% | Beat |
| 24 Mar 2021 16:00 | -0.22 | -0.44 | -98.2% | Miss |
| 29 Oct 2020 16:00 | -0.37 | -0.33 | +11.3% | Beat |
| 10 Aug 2020 17:00 | -0.69 | -0.43 | +37.5% | Beat |
| 11 May 2020 17:00 | -0.61 | -0.80 | -30.5% | Miss |
| 25 Feb 2020 07:00 | -0.68 | -0.51 | +25.0% | Beat |
| 04 Nov 2019 07:00 | -1.14 | -0.96 | +15.8% | Beat |
| 12 Aug 2019 07:00 | -0.84 | -1.32 | -57.0% | Miss |
| 30 Apr 2019 16:00 | -0.62 | -0.82 | -31.7% | Miss |
| 18 Mar 2019 16:00 | -0.54 | -0.49 | +9.2% | Beat |
| 05 Nov 2018 16:00 | -0.42 | -0.38 | +8.4% | Beat |
| 02 Aug 2018 07:00 | -0.32 | -0.35 | -7.5% | Miss |
| 10 May 2018 16:00 | -0.36 | -0.30 | +16.7% | Beat |
| 29 Mar 2018 08:00 | -0.30 | -0.11 | +62.7% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 297.2M | +11.6% | -51.6M | -17.4% | -0.80 | +1.2% | -50.7M |
| 2024 | 266.3M | +31.8% | -50.4M | -18.9% | -0.81 | +25.0% | -22.8M |
| 2023 | 202.1M | +36.0% | -61.7M | -30.5% | -1.08 | +18.8% | -35.6M |
| 2022 | 148.6M | — | -74.4M | -50.1% | -1.33 | — | -87.9M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 02 Dec 2024 – 06 Dec 2024 | 13.40 | 13.81 | 12.55 | 12.66 | -7.52% | 1,954,600 | |
| 25 Nov 2024 – 29 Nov 2024 | 12.75 | 14.33 | 12.49 | 13.69 | +8.65% | 2,306,400 | |
| 18 Nov 2024 – 22 Nov 2024 | 12.12 | 13.25 | 11.88 | 12.60 | +4.05% | 3,408,900 | |
| 11 Nov 2024 – 15 Nov 2024 | 13.74 | 13.88 | 11.37 | 12.11 | -11.48% | 4,116,300 | |
| 04 Nov 2024 – 08 Nov 2024 | 16.65 | 17.44 | 13.35 | 13.68 | -18.33% | 4,996,700 | |
| 28 Oct 2024 – 01 Nov 2024 | 16.61 | 16.98 | 15.95 | 16.75 | +1.76% | 1,774,600 | |
| 21 Oct 2024 – 25 Oct 2024 | 16.65 | 16.69 | 15.51 | 16.46 | -0.96% | 2,551,900 | |
| 14 Oct 2024 – 18 Oct 2024 | 16.92 | 17.82 | 16.37 | 16.62 | -1.66% | 3,207,300 | |
| 07 Oct 2024 – 11 Oct 2024 | 16.24 | 17.18 | 15.99 | 16.90 | +3.43% | 2,785,600 | |
| 30 Sep 2024 – 04 Oct 2024 | 15.75 | 17.59 | 15.75 | 16.34 | +2.45% | 2,804,000 | |
| 23 Sep 2024 – 27 Sep 2024 | 16.57 | 16.73 | 15.31 | 15.95 | -3.63% | 3,067,400 | |
| 16 Sep 2024 – 20 Sep 2024 | 17.58 | 17.70 | 16.09 | 16.55 | -5.37% | 3,713,400 | |
| 09 Sep 2024 – 13 Sep 2024 | 14.55 | 17.59 | 14.52 | 17.49 | +18.90% | 4,344,800 | |
| 03 Sep 2024 – 06 Sep 2024 | 15.85 | 16.28 | 14.62 | 14.71 | -7.43% | 1,285,600 | |
| 26 Aug 2024 – 30 Aug 2024 | 15.89 | 16.25 | 15.48 | 15.89 | +0.19% | 2,074,700 | |
| 19 Aug 2024 – 23 Aug 2024 | 14.39 | 16.29 | 14.29 | 15.86 | +10.52% | 3,585,800 | |
| 12 Aug 2024 – 16 Aug 2024 | 13.02 | 14.52 | 12.99 | 14.35 | +10.73% | 2,946,900 | |
| 05 Aug 2024 – 09 Aug 2024 | 12.90 | 13.46 | 12.68 | 12.96 | -6.49% | 2,163,600 | |
| 29 Jul 2024 – 02 Aug 2024 | 12.30 | 14.41 | 12.00 | 13.86 | +12.59% | 3,554,600 | |
| 22 Jul 2024 – 26 Jul 2024 | 12.19 | 12.67 | 11.82 | 12.31 | +2.93% | 1,485,100 | |
| 15 Jul 2024 – 19 Jul 2024 | 11.80 | 12.41 | 11.61 | 11.96 | +1.61% | 1,640,100 | |
| 08 Jul 2024 – 12 Jul 2024 | 11.10 | 11.98 | 10.85 | 11.77 | +7.69% | 1,935,500 | |
| 01 Jul 2024 – 05 Jul 2024 | 10.83 | 11.11 | 10.63 | 10.93 | +0.74% | 1,293,400 | |
| 24 Jun 2024 – 28 Jun 2024 | 10.60 | 11.00 | 10.24 | 10.85 | +2.84% | 4,183,900 | |
| 17 Jun 2024 – 21 Jun 2024 | 11.33 | 11.42 | 10.32 | 10.55 | -6.88% | 2,843,300 |
Page 5 of 11
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Evolus, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 07 Nov 2026 18:36
- Evolus (EOLS) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 16:28
- Evolus Inc (EOLS) (Q3 2026) Earnings Call Highlights: Fourth Consecutive Positive Adjusted ... (opens in a new tab) GuruFocus.com · 05 Nov 2026 13:09
- BTIG Maintains Buy on Evolus, Raises Price Target to $15 (opens in a new tab) Benzinga · 05 Nov 2026 06:18
- What Evolus (EOLS) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 05 Nov 2026 02:14
- Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates (opens in a new tab) Zacks · 04 Nov 2026 23:45
- Evolus, Inc. (EOLS) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 04 Nov 2026 22:04
- Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook (opens in a new tab) 04 Nov 2026 21:05
- Evolus Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 04 Nov 2026 18:14
- Evolus Affirms FY2026 Sales Guidance of $330.000M-$337.000M vs $334.100M Est (opens in a new tab) Benzinga · 04 Nov 2026 17:39
- Evolus Q3 EPS $(0.19) Misses $(0.17) Estimate, Sales $78.000M Beat $77.662M Estimate (opens in a new tab) Benzinga · 04 Nov 2026 17:28
- FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective Action (opens in a new tab) Stocktwits · 02 Oct 2026 18:41
- Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future (opens in a new tab) Insider Monkey · 09 Sep 2026 07:10
- Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet (opens in a new tab) Zacks · 27 Aug 2026 14:55
- Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade (opens in a new tab) Zacks · 11 Aug 2026 14:55
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 6.80 USD
- Market cap
- 450.4M
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 | — |
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 10.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 8.2 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 50: three or more warnings
- Thin interest cover: operating profit is only -1.9× the interest
- The last full year was a loss
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | 23.26× | Fair | 14.89× |
| Price / book | -11.9× | Weak | 3.81× |
| Price / sales | 1.38× | Good | 3.19× |
| EV / EBITDA | -69.4× | Weak | 12.63× |
| Free cash flow yield | 3% | Fair | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 66.1% | Good | 58.6% |
| Operating margin | -7.4% | Weak | 7.8% |
| Net margin | -9.6% | Weak | 2.8% |
| Return on assets | -4.4% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 26% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | -6.71× | Good | 0.48× |
| Interest cover | -1.91× | Weak | 2.69× |
| Current ratio | 1.42× | Fair | 2.39× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow EOLS and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.